The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Inhaler Corticosteroid Device Market Expected To Reach Based On Its 2026 Value?
The inhaler corticosteroid device market has seen substantial growth in recent years. Its value is projected to rise from $16.83 billion in 2025 to $17.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this market’s expansion was driven by the increasing prevalence of asthma and COPD, rising awareness concerning inhaler therapies, governmental initiatives for respiratory health, advancements in metered-dose inhalers, and the expansion of hospital and homecare facilities.
The inhaler corticosteroid device market is projected to experience substantial expansion over the upcoming years. It is set to reach a value of $23.18 billion by 2030, advancing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period can be primarily attributed to factors such as the integration of AI and IoT into inhaler devices, the development of eco-friendly inhalers, the expansion of telehealth services, personalized medication delivery approaches, and increasing demand from emerging markets. Furthermore, major trends anticipated within the same forecast timeframe involve smart inhaler integration, personalized dosage management, telehealth-enabled monitoring, the design of eco-friendly and sustainable devices, and advancements in aerosol delivery technologies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp
What Major Factors Are Driving The Inhaler Corticosteroid Device Market Forward?
The escalating occurrence of respiratory ailments is anticipated to propel the expansion of the inhaler corticosteroid device market going forward. Respiratory diseases are a spectrum of conditions affecting the lungs and airways, impeding individuals’ ability to breathe correctly and effectively. The increasing prevalence of these diseases stems from rising air pollution, which exposes people to harmful particles that damage lung tissue and trigger chronic issues such as asthma and bronchitis. Inhaler corticosteroid devices are utilized to manage respiratory diseases by delivering anti-inflammatory medication directly into the lungs, helping to diminish inflammation and improve breathing. For instance, in June 2025, the Office for Health Improvement and Disparities, a UK-based government department, reported that in the financial year ending 2024, England recorded 854,922 emergency hospital admissions for respiratory diseases, corresponding to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, marking a 7% increase compared to the previous year. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the inhaler corticosteroid device market.
How Is Segmentation Applied In The Inhaler Corticosteroid Device Market Segment Analysis?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
Which Trends Are Impacting The Progress Of The Inhaler Corticosteroid Device Market?
Major companies operating in the inhaler corticosteroid device market are concentrating on introducing innovative solutions, such as rescue inhalers that integrate albuterol and budesonide, to enhance treatment effectiveness and provide patients with a more convenient, dual-action therapy from a single device. An inhaler combining albuterol and budesonide functions as a dual-action rescue inhaler that delivers both a bronchodilator (albuterol) to quickly open the airways and a corticosteroid (budesonide) to reduce inflammation, offering rapid symptom relief and long-term asthma control in one device. For instance, in January 2024, AstraZeneca PLC, a UK-based pharmaceutical industry company, introduced AIRSUPRA, which is the first and only FDA-approved rescue inhaler combining albuterol and budesonide for adults with asthma. This inhaler is formulated for as-needed application to both relieve acute bronchoconstriction symptoms and decrease airway inflammation, thereby lowering the risk of severe asthma exacerbations. It embodies a novel strategy by bringing together a short-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in a singular inhaler, with its approval based on clinical trials that demonstrated its superiority over albuterol used alone in preventing asthma attacks.
Who Are The Companies Participating In The Inhaler Corticosteroid Device Market Environment?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH
Get The Full Inhaler Corticosteroid Device Market Report:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
Which Region Is The Largest In The Inhaler Corticosteroid Device Market?
North America was the largest region in the inhaler corticosteroid device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Inhaler Corticosteroid Device Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp
Browse Through More Reports Similar to the Global Inhaler Corticosteroid Device Market 2026, By The Business Research Company
Implantable Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/implantable-infusion-pumps-global-market-report
Intravenous Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-infusion-pumps-global-market-report
Ambulatory Iv Infusion Pumps Market Report 2026
https://www.thebusinessresearchcompany.com/report/ambulatory-iv-infusion-pumps-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model